Synthetic peptides as cancer vaccines.
Effective cancer therapy or prevention has been the dream of physicians and scientists for many years. Although we are still very far from our ultimate goal of cancer prevention, significant milestones have been realized in terms of our knowledge base and understanding of the pathogenesis of cancerous cells and the involvement of the immune system against both self- and virus-associated tumor antigens. Immunotherapeutic strategies are now accepted to being superior in terms of the exquisite specificity that they offer in targeting only tumor cells as opposed to the existent chemotherapy or radiation therapy that is more general and invasive with many associated side effects. There are several immunotherapeutic strategies that are currently under investigation. This review primarily focuses on the significant advances made in the use of synthetic peptides in the development of subunit cancer vaccines. We have attempted to highlight some of the fundamental issues regarding antigen processing and presentation, Major Histocompatibility Complex (MHC) restriction, T-cell help, structural determinants in antibody recognition, and the use of these concepts in the rational design and delivery of peptide vaccines to elicit protective humoral and cell mediated immune responses. The recent use of costimulatory molecules and cytokines to augment immune responses also has been discussed along with the contributions of our laboratory to the field of synthetic peptide vaccine development.
Sundaram
Roshni
R
Department of Microbiology, The Ohio State University, Columbus 43210, USA.
Dakappagari
Naveen K
NK
Kaumaya
Pravin T P
PT
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D001402:B-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016207:Cytokines / Q000008:administration & dosage; D015195:Drug Design; D000939:Epitopes; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology / Q000627:therapeutic use*; D015202:Protein Engineering; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D016207:Cytokines; D000939:Epitopes; D010455:Peptides; D019444:Vaccines, DNA